5-Amino-1MQ Also known as: 5-amino-1-methylquinolinium, NNMTi TL;DR Increases intracellular NAD+ levels via NNMT inhibition (preclinical) Reduces body weight and white adipose mass in diet-induced obese mice Improves grip strength by up to 60% in aged mice when combined with exercise Suppresses lipogenesis in adipocytes without affecting food intake Community-Reported Side EffectsAnecdotal
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
Amino Acids, 31 , 251-272
Cadmium or cadmium compounds and chronic kidney disease in workers and the general population: a systematic review
Joint pain, weakness, or stiffness that affects exercise, sleep, or daily life, especially if theres swelling, redness, or tenderness and warmth around the joint
Yes, the calculator accepts any vial size
